Wellbutrin SR

See also: Generic Wellbutrin, Generic Wellbutrin XL

Wellbutrin SR is a brand name of bupropion, approved by the FDA in the following formulation(s):

WELLBUTRIN SR (bupropion hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: October 4, 1996
  
  Strength(s): 100MG ^[AB1], 150MG ^[RLD][AB1]


• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 14, 2002
  
  Strength(s): 200MG ^[AB1]

Has a generic version of Wellbutrin SR been approved?

A generic version of Wellbutrin SR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Wellbutrin SR and have been approved by the FDA:

bupropion hydrochloride tablet, extended release; oral

• 
  Manufacturer: ACTAVIS
  
  Approval date: March 12, 2008
  
  Strength(s): 150MG ^[AB1]


• 
  Manufacturer: ACTAVIS
  
  Approval date: July 19, 2010
  
  Strength(s): 100MG ^[AB1], 200MG ^[AB1]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: June 9, 2011
  
  Strength(s): 100MG ^[AB1], 150MG ^[AB1], 200MG ^[AB1]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: January 28, 2004
  
  Strength(s): 100MG ^[AB1]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: March 22, 2004
  
  Strength(s): 150MG ^[AB1]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: December 3, 2004
  
  Strength(s): 200MG ^[AB1]


• 
  Manufacturer: MYLAN
  
  Approval date: April 8, 2010
  
  Strength(s): 100MG ^[AB1], 150MG ^[AB1], 200MG ^[AB1]


• 
  Manufacturer: SANDOZ
  
  Approval date: November 25, 2003
  
  Strength(s): 100MG ^[AB1]


• 
  Manufacturer: SANDOZ
  
  Approval date: March 22, 2004
  
  Strength(s): 150MG ^[AB1]


• 
  Manufacturer: SANDOZ
  
  Approval date: June 22, 2005
  
  Strength(s): 200MG ^[AB1]


• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: April 6, 2010
  
  Strength(s): 100MG ^[AB1], 150MG ^[AB1], 200MG ^[AB1]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: March 24, 2009
  
  Strength(s): 100MG ^[AB1], 150MG ^[AB1], 200MG ^[AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wellbutrin SR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
  Patent 5,358,970
  Issued: October 25, 1994
  Inventor(s): Ruff; Michael D. & Kalidindi; Sanyasi R. & Sutton, Jr.; Joel E.
  Assignee(s): Burroughs Wellcome Co.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Controlled sustained release tablets containing bupropion
  Patent 5,427,798
  Issued: June 27, 1995
  Inventor(s): Ludwig; Jennie Sue G. & Bass, Jr.; William L. & Sutton, Jr.; Joel E.
  Assignee(s): Burroughs Wellcome Co.
  A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Stabilized pharmaceutical composition containing bupropion
  Patent 5,731,000
  Issued: March 24, 1998
  Inventor(s): Ruff; Michael David & Kalidindi; Sanyasi Raju & Sutton, Jr.; Joel Elmore
  Assignee(s): Glaxo Wellcome Inc.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Stabilized pharmaceutical
  Patent 5,763,493
  Issued: June 9, 1998
  Inventor(s): Ruff; Michael D. & Kalidindi; Sanvasi R. & Sutton, Jr.; Joel Elmore
  Assignee(s): Glaxo Wellcome Inc.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  

See also...

• Wellbutrin SR Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Wellbutrin SR Consumer Information (Cerner Multum)
• Wellbutrin SR Advanced Consumer Information (Micromedex)
• Bupropion Consumer Information (Drugs.com)
• Bupropion Consumer Information (Wolters Kluwer)
• Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Consumer Information (Cerner Multum)
• Bupropion Advanced Consumer Information (Micromedex)
• Bupropion Hydrochloride AHFS DI Monographs (ASHP)